Q2 Earnings Estimate for LABT Issued By Zacks Research

Lakewood-Amedex Biotherapeutics Inc. (NASDAQ:LABT) – Investment analysts at Zacks Research issued their Q2 2026 earnings per share estimates for shares of Lakewood-Amedex Biotherapeutics in a report issued on Tuesday, June 23rd. Zacks Research analyst D. Bautz forecasts that the company will post earnings per share of $0.65 for the quarter. Zacks Research also issued estimates for Lakewood-Amedex Biotherapeutics’ Q3 2026 earnings at $0.56 EPS, Q4 2026 earnings at $0.48 EPS, FY2026 earnings at $2.52 EPS, FY2027 earnings at $1.32 EPS and FY2028 earnings at $1.16 EPS.

Separately, Wall Street Zen lowered shares of Lakewood-Amedex Biotherapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, May 30th.

Lakewood-Amedex Biotherapeutics Trading Down 6.3%

Shares of LABT stock opened at $3.72 on Thursday. Lakewood-Amedex Biotherapeutics has a 1-year low of $3.42 and a 1-year high of $98.20. The stock’s fifty day simple moving average is $14.06.

Lakewood-Amedex Biotherapeutics Company Profile

We are a biotechnology company focused on leveraging unique, pioneering science to address unmet needs in the treatment of infectious diseases, improving patient outcomes, and significantly reducing the threat posed by antibiotic-resistant bacterial strains, including methicillin resistant Staphylococcus aureus (MRSA), vancomycin resistant Enterococci species (VRE), and others. Antimicrobial resistance (AMR) represents a growing global health crisis, being directly responsible for 1.27 million deaths annually and contributing to nearly 5 million deaths worldwide.